WO2006018632A3 - Cell therapy with exo 1 - Google Patents

Cell therapy with exo 1 Download PDF

Info

Publication number
WO2006018632A3
WO2006018632A3 PCT/GB2005/003211 GB2005003211W WO2006018632A3 WO 2006018632 A3 WO2006018632 A3 WO 2006018632A3 GB 2005003211 W GB2005003211 W GB 2005003211W WO 2006018632 A3 WO2006018632 A3 WO 2006018632A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell therapy
exo
treatment
methods
relates
Prior art date
Application number
PCT/GB2005/003211
Other languages
French (fr)
Other versions
WO2006018632A2 (en
Inventor
Laura Maringele
Original Assignee
Univ Newcastle
Laura Maringele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle, Laura Maringele filed Critical Univ Newcastle
Publication of WO2006018632A2 publication Critical patent/WO2006018632A2/en
Publication of WO2006018632A3 publication Critical patent/WO2006018632A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
    • C12Y301/11001—Exodeoxyribonuclease I (3.1.11.1)

Abstract

The invention relates to cell therapy, and in particular to the use of exol gene and the EXO1 enzyme in medicine, and to the uses thereof in treatment and therapy of various diseases. In particular, the invention relates to the treatment or prevention of cancer and/or aging, and to methods of carrying out such methods, including recombinant constructs encoding EXO1.
PCT/GB2005/003211 2004-08-18 2005-08-17 Cell therapy with exo 1 WO2006018632A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0418388.5 2004-08-18
GBGB0418388.5A GB0418388D0 (en) 2004-08-18 2004-08-18 Cell therapy

Publications (2)

Publication Number Publication Date
WO2006018632A2 WO2006018632A2 (en) 2006-02-23
WO2006018632A3 true WO2006018632A3 (en) 2006-05-04

Family

ID=33042231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003211 WO2006018632A2 (en) 2004-08-18 2005-08-17 Cell therapy with exo 1

Country Status (2)

Country Link
GB (1) GB0418388D0 (en)
WO (1) WO2006018632A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157747A1 (en) * 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
EP2077335A1 (en) * 2007-12-22 2009-07-08 Universitätsklinikum Schleswig-Holstein EXO1 promoter polymorphism associated with exceptional life expectancy in humans
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
WO2014089124A1 (en) 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
AR096673A1 (en) * 2013-06-19 2016-01-27 Buck Inst For Res On Aging METHODS TO INCREASE THE EFFECTIVENESS OF MEDICAL THERAPIES
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023066A1 (en) * 1993-03-30 1994-10-13 United States Biochemical Corporation Use of exonuclease in dna sequencing
US20020004235A1 (en) * 2000-03-21 2002-01-10 Moffett Robert B. Stable composition comprising a nuclease and a phosphatase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023066A1 (en) * 1993-03-30 1994-10-13 United States Biochemical Corporation Use of exonuclease in dna sequencing
US20020004235A1 (en) * 2000-03-21 2002-01-10 Moffett Robert B. Stable composition comprising a nuclease and a phosphatase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FIORENTINI PAOLA ET AL: "Exonuclease I of Saccharomyces cerevisiae functions in mitotic recombination in vivo and in vitro", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 17, no. 5, May 1997 (1997-05-01), pages 2764 - 2773, XP002176159, ISSN: 0270-7306 *
MARINGELE LAURA ET AL: "EXO1 plays a role in generating type I and type II survivors in budding yeast", GENETICS, vol. 166, no. 4, April 2004 (2004-04-01), pages 1641 - 1649, XP002362616, ISSN: 0016-6731 *
SUN XUEMIN ET AL: "Functional alterations of human exonuclease 1 mutants identified in atypical Hereditary Nonpolyposis Colorectal Cancer syndrome", CANCER RESEARCH, vol. 62, no. 21, 1 November 2002 (2002-11-01), pages 6026 - 6030, XP002362614, ISSN: 0008-5472 *
TRAN P T ET AL: "EXO1-A multi-tasking eukaryotic nuclease", DNA REPAIR, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 12, 2 December 2004 (2004-12-02), pages 1549 - 1559, XP004595463, ISSN: 1568-7864 *
WEI KAICHUN ET AL: "Inactivation of exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility.", GENES AND DEVELOPMENT, vol. 17, no. 5, 1 March 2003 (2003-03-01), pages 603 - 614, XP002362615, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
GB0418388D0 (en) 2004-09-22
WO2006018632A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2006018632A3 (en) Cell therapy with exo 1
WO2005063819A3 (en) Human binding molecule against cd1a
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2003025149A8 (en) Cell populations which co-express cd49c and cd90
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase